SCHEMBL16615900

SCHEMBL16615900

Cc1ncc(CNC(=O)c2cnc(CNS(=O)(=O)c3cc4ccccc4s3)cn2)s1

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GRIN2A Q12879 4/20 0.61
GRIN1 Q05586 2/20 0.61
GRIN2B Q13224 1/20 0.49
NAMPT P43490 2/20 0.36
SLC8A1 P32418 1/20 0.35
CASP3 P42574 1/20 0.35
KDM4E B2RXH2 1/20 0.35
PKM P14618 1/20 0.35
TPSAB1 Q15661 1/20 0.35
DRD2 P14416 2/20 0.35
HTR2A P28223 2/20 0.35
HTR7 P34969 2/20 0.35
HTR6 P50406 2/20 0.35
RAB9A P51151 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
HDAC1 Q13547 1/20 0.34
KIT P10721 1/20 0.34
NPY5R Q15761 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16615839 0.88 GRIN2A (0.49) GRIN2AGRIN1GRIN2BKDM4ETPSAB1
SCHEMBL16615942 0.83 GRIN2A (0.63) GRIN2AGRIN1GRIN2BKDM4EPKM
SCHEMBL16598319 0.81 GRIN2A (0.69) GRIN2AGRIN1GRIN2BCASP3
SCHEMBL16615832 0.79 GRIN2A (0.78) GRIN2AGRIN1GRIN2BCASP3PKM
SCHEMBL16615933 0.79 GRIN2A (0.77) GRIN2AGRIN1GRIN2BCASP3KDM4E
SCHEMBL16598210 0.79 GRIN2A (0.74) GRIN2AGRIN1GRIN2BNAMPTSLC8A1
SCHEMBL16598350 0.79 GRIN2A (0.77) GRIN2AGRIN1GRIN2BNAMPTCASP3
SCHEMBL16598003 0.78 GRIN2A (0.85) GRIN2AGRIN1GRIN2BCASP3
SCHEMBL16598233 0.78 GRIN2A (0.85) GRIN2AGRIN1GRIN2BCASP3KDM4E
SCHEMBL16615940 0.78 GRIN2A (0.68) GRIN2AGRIN1GRIN2BCASP3PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9963434-B2 N-arylmethyl sulfonamide negative modulators of NR2A LUC THERAPEUTICS, INC. (US) 2018-05-08 US disclosed
US-9963434-B2 N-arylmethyl sulfonamide negative modulators of NR2A LUC THERAPEUTICS, INC. (US) 2018-05-08 US disclosed
US-20160311782-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A NOVARTIS AG (CH) 2016-10-27 US disclosed
US-20160311782-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A NOVARTIS AG (CH) 2016-10-27 US disclosed
US-20150141433-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A MNEMOSYNE PHARMACEUTICALS, INC. 2015-05-21 US disclosed
US-20150141433-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A MNEMOSYNE PHARMACEUTICALS, INC. 2015-05-21 US disclosed
WO-2015048503-A2 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A MNEMOSYNE PHARMACEUTICALS, INC. (US) 2015-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160311782-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A GRIN2A, GRIN2B, NR2C2 GRIN2A 1/4885GRIN1 5/4885GRIN2B 2/4885
US-20150141433-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A GRIN2A, GRIN2B, NR2C2 GRIN2A 1/4885GRIN1 5/4885GRIN2B 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.